Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries SciSparc Ltd. - Ordinary Shares (NQ: SPRC ) 0.7085 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about SciSparc Ltd. - Ordinary Shares < Previous 1 2 3 4 Next > SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million July 17, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification July 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss July 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company July 08, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Secures Strategic Advantage with Grant of European Patent May 31, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc to Acquire AutoMax April 11, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression March 27, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research March 21, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Granted Another Patent, Strengthening its Core Technology in Canada March 18, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial March 14, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure March 12, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder March 08, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe March 07, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology March 06, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing February 29, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder January 29, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement January 24, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million January 19, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments January 04, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments January 04, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform December 13, 2023 From SciSparc Ltd Via GlobeNewswire SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel December 07, 2023 From SciSparc Ltd Via GlobeNewswire Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial December 01, 2023 From SciSparc Ltd Via GlobeNewswire SciSparc Adopts Limited Duration Shareholder Rights Plan November 28, 2023 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment November 28, 2023 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform November 27, 2023 From SciSparc Ltd Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.